(See the Editorial Commentary by Klompas on pages 76-8.)
Hospital-acquired pneumonia (HAP), and notably ventilator-associated pneumonia, developing as a consequence of lung bacterial colonization, alters clinically important outcomes, including duration of mechanical ventilation, length of stay in the intensive care unit (ICU), and mortality rates [1] [2] [3] . HAP is associated with use of antibiotics that may increase the risk of multiple-drug-resistant bacteria in ICUs, and the increase in medical costs is estimated to be to $20 000 per episode of HAP [4] . Given HAP-associated morbidity, the prevention of HAP has been the focus of numerous studies in critically ill patients and remains a controversial issue.
Bacterial colonization of the oropharynx and subsequent microaspirations are initial events that lead to HAP [5] [6] [7] . The prevention of such events was therefore proposed as a method for reducing the rate of HAP and presumably for reducing associated morbidity and mortality. Three main approaches have been evaluated: (1) diminishing the microaspiration of digestive flora; (2) reducing the volume of oropharyngeal secretions aspirated into the lungs; and (3) inhibiting overgrowth or alterations in the microbiome in the oropharynx or larynx. Several meta-analyses of approaches to reducing the incidence of HAP conclude to a reduction in the risk of infection of such strategies. However, international recommendations for the prevention of HAP provide different conclusions [8] [9] [10] [11] and do not state which intervention is mandatory or superior to the others. The combination of several strategies for preventing HAP failed to improve mortality rates [12] , and nonadherence to international guidelines for HAP prevention is common [13] .
We have hypothesized that all the preventive strategies do not equally alter the risk of death. Because many interventions are often poorly applied in clinical practice, it is important to determine the most effective interventions that should be implemented in critically ill patients. We thus performed a systematic review to determine which method is the most effective for decreasing mortality rates. The rates of HAP, duration of mechanical ventilation, and ICU length of stay were also evaluated as secondary criteria.
MATERIALS AND METHODS

Data Source and Searches
We followed PRISMA (Preferred Reported Items for Systemic Reviews and Meta-Analyses) guidelines were followed during the design and implementation of this meta-analysis (Supplementary Table 1 ). We attempted to identify all relevant studies published in English regardless of publication status ( published or in press). We considered abstracts presented at scientific meetings <3 years earlier (Society Of Critical Care Medicine, European Society of Intensive Care Medicine, Societé Française d'Anesthesie Reanimation, Societé de Reanimation de Langue Française). PubMed (MEDLINE/Index Medicus) and the Cochrane Controlled Trials Register were searched for studies published from January 1969 through 10 June 2014. The Medical Subject Heading terms used for the search were pneumonia and intensive care units with the limit "adult 19+ years." The "related articles" hyperlinks in MEDLINE were explored for additional references. The reference lists of all selected trials and previous published meta-analysis were checked for additional references. We contacted authors to identify unpublished data.
Study Selection
The authors selected all randomized trials that evaluated any of the following strategies in adult patients (aged ≥18 years) hospitalized in ICUs: acidified enteral feeding, selective digestive decontamination (SDD), early enteral feeding, postpyloric enteral feeding, decreased gastric retention, probiotic/symbiotic therapies, ulcer prophylaxis, aerosolized antibiotics, closed suctioning systems, early tracheotomy, humidification, phytotherapy (ginger extract), physiotherapy, positive end-expiratory pressure (PEEP), tracheal saline instillation, silver-coated endotracheal tubes), selective oropharyngeal decontamination (SOD), patient position, sinusitis prophylaxis, subglottic secretion drainage, and tracheal cuff monitoring. Studies using a cluster-randomization procedure were included in the main analysis, but a sensitive analysis with exclusion of such studies was planned a priori. Pediatric patients were excluded from the study.
Data Extraction and Quality Assessment
One author (A. R.) checked all titles and abstracts of the articles identified from the database research and examined in full all randomized trials potentially eligible for the review. Quality assessment for each study was performed by 2 unblinded investigators (A. R. and K. A.). Any disagreement among the 2 authors was resolved by discussion. Persistent disagreement was settled by discussion with other authors (E. M. and E. A.) after separate review of the report.
One author (A. R.) designed a standard data extraction form, and other authors (E. M., E. A., and K. A.) amended and validated the design of the form before abstraction of data. One author (A. R.) extracted the following data from each eligible study: first author, year of publication, quality assessment by the Cochrane Collaboration's risk of bias tool, type of intervention, inclusion criteria, criteria used for HAP diagnosis, number of patients, number of HAP cases, duration of mechanical ventilation and of ICU stay, and ICU mortality rate. Data were extracted from the tables, figures, text of the manuscript, and/or from previous meta-analysis that included the selected trial.
Data Synthesis and Analysis
The primary evaluation criterion was the rate of in-ICU deaths, that is, the ICU mortality rate. When no information was available on in-ICU deaths, the rate of in-hospital death was considered if provided. When trials had 2 control arms, the numbers of deaths in the control arms were pooled. The other end points analyzed included the incidence of HAP, the duration of mechanical ventilation, and the ICU length of stay (or duration of hospitalization, as provided).
Statistical Analyses
All statistical analyses were performed using Review Manager software (version 5.1.6; Cochrane Collaboration; Nordic Cochrane Centre) or Stata software (version 10.1; StataCorp). For dichotomous data (mortality and HAP), we calculated the risk ratio (RR) with 95% confidence intervals (CIs). To estimate the clinical relevance of a beneficial effect on mortality, we calculated the number needed to treat with 95% CIs, using RR and control event rates if the RR was significant. For continuous data, weighted mean differences with 95% CIs were calculated.
Heterogeneity was determined using the I 2 statistics. All pooled estimates used the random effects model. A sensitivity analysis was achieved with the exclusion of cluster-randomized trial [14] .
In exploratory analyses, we compared the effects of SDD on mortality rates, based on the administration of systemic antimicrobial therapy (or not), population (trauma and surgical vs medical or mixed population), sample size (>200 or <200 patients), and risk of bias (double blinding and randomization). To evaluate publication bias for trials that studied SDD, we constructed a funnel plot and carried out Egger regression intercept and Begg rank correlation tests to assess asymmetry. The precision of each trial was evaluated according to the standard error of logarithm RR. Egger test and Begg rank test results were considered significant at P < .10 because these tests have low power. We finally performed a meta-regression analysis to explore the possible interaction between the mortality rate (baseline risk) in the control group and the effect of SDD. Differences were considered statistically significant at P < .05.
Role of the Funding Source
None of the institutions/sponsors of individual author had any role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; or preparation, review, or approval of the manuscript. The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit the manuscript for publication. Figure 1 presents the overall search approach. Our initial searches identified 1113 studies in MEDLINE and 465 studies Total 146 studies because one study comparing 1 control group to 2 intervention groups (1 digestive method and 1 oro-pharyngeal method) was counted twice.
RESULTS
Identification of the Trials
in the Cochrane Controlled Trials Register. After duplicate titles and abstracts were removed, 1220 citations were excluded (1041 nonrandomized trials and 179 irrelevant citations). The remaining 278 studies were considered potentially eligible and were accessed for full-text review. After exclusion of 117 trials (103 nonrandomized, 8 without outcomes of interest, 6 with abstracts >3 years old), we included 157 evaluable trials, of which 145 provided the mortality rate.
Description of Recorded Outcomes and Tested Interventions
Supplementary Table 2 summarizes the characteristics of the included clinical trials. Fifteen trials (9.6%) had >2 arms: 7 (5%) compared 1 control group with 2 interventional groups combined for analysis, 1 (1%) compared 1 control group with 2 interventional groups considered separately for the analysis; 5 (3.2%) compared 1 interventional group with 2 control groups combined for analysis. For 2 trials with a 2 × 2 design, the 3 intervention groups (two groups with one of the interventions and one group with the association of the two interventions) were combined and compared with the doubledummy (none of the intervention) group. One trial with a 2 × 2 design compared patients who received continuous subglottic secretion drainage or control and ulcer prophylaxis with either H2-receptor antagonist or aluminate, no placebo was used for ulcer prophylaxis, and only 2 arms were thus considered for the analyses (subglottic secretion drainage vs control).
Description of Participants
Fifteen studies (9.6%) included medical ICU patients, 46 (29.2%) included surgical or trauma ICU patients, and 96 (61.1%) included mixed ICU populations. Figure 2 . Hospital mortality rates in critically ill patients receiving a strategy for preventing hospital-acquired pneumonia. All pooled estimates used the random effects model. Boldface P values indicate significant differences (P < .05). Abbreviations: CI, confidence interval; ET, endotracheal tube; NA, not applicable; PEEP, positive end-expiratory pressure; RCT, randomized controlled trial; SDD, selective digestive decontamination; SOD, selective oropharyngeal decontamination.
Risk of Bias in the Included Studies
The risks for bias are presented in Supplementary Table 3. All studies were randomized; the risk of bias for allocation concealment was low in 98 studies (62%). The risks of performance (doubleblind study) and detection bias (blinding of outcome assessment) were low in 52 (33.1%) and 89 (56.7%) of the studies, respectively. Table 4 ). The funnel plot showed no evidence for asymmetry and does not suggest publication bias or other bias (Egger test, P = .17; Begg test, P = .69) ( Figure 3B ). In subgroup analyses, the RR for in-ICU death was 0.78 (95% CI, .69-.90; P < .001; I 2 = 40%) in trials investigating SDD with systemic antimicrobial therapy and 1.01 (95% CI, .85-1.21; P = .91; I 2 = 0%) in trials without systemic antimicrobial therapy (Supplementary Tables 4 and 5 ). Given the risk of selection of resistant bacteria with antimicrobial therapies [44] , defining the population in which SDD is more effective is an important in assessing the use of such therapy. We thus investigated the association between the effects of SDD and mortality rate in the control group (a proxy for baseline risk). In meta-regression analysis, there was a trend toward a positive interaction between the rate of death in the control groups and benefit from SDD (P = .07; Figure 3C ).
Effect of Interventions
Secondary Outcomes
The (Figure 4) , the RR for HAP was reduced in trials evaluating SDD versus placebo (P < .001), postpyloric versus gastric enteral feeding (P = .02), PEEP versus no PEEP (P = .02), tracheal saline instillation versus standard secretion drainage (P = .009), aerosolized antibiotic versus placebo (P = .04), silver-coated versus classic endotracheal tube (P = .002), SOD versus standard oral care (P < .001), and subglottic versus routine secretion drainage (P < .001). The duration of mechanical ventilation was reported in 85 studies (23 691 patients) and showed high heterogeneity across studies (I 2 = 84%). The duration of mechanical ventilation was reduced in the intervention groups compared with the control groups (weighted mean difference, −0.75 days (95 CI%, −1.16 to −.35; P < .001). When each intervention is analyzed separately ( Figure 5 ), the duration of mechanical ventilation was reduced in trials evaluating SDD versus standard care or placebo (P = .003) and physiotherapy versus standard care (P = .03). The duration of the ICU stay was reported in 82 studies (22 718 patients). It was reduced in the intervention groups compared with the control groups (weighted mean difference, −1.13 days [95 CI%, −1.70, −.57; P < .001; I 2 = 89%]). When each intervention is analyzed separately (Figure 6 ), the duration of ICU stay was reduced in trials evaluating phytotherapy (ginger extract) versus placebo (P < .001) or SOD versus standard oral care (P = .03).
DISCUSSION
For this systematic review, we performed an extensive literature search with few limits regarding publication status, thereby minimizing the risk of missing important studies. This metaanalysis shows that SDD is the main intervention decreasing the mortality rate in critically ill patients. It is widely accepted that HAP increases morbidity and mortality rates in critically ill patients [45, 46] . In the current results, there is a paradox between the sharp reduction in the rate of HAP and the small reductions in death rates and time on ventilators [47] . This paradox may be attributable to the systemic diffusion of prophylactic antibiotics used for the SDD [48, 49] , which can alter the accuracy of the bacteriological samples and thus increase the rate of false-negatives in the diagnosis of HAP. Moreover, the diagnosis of HAP has a low specificity and high interobserver variability [50] , and there are major discrepancies between the clinical diagnoses of HAP and the autopsy findings in critically ill patients [51, 52] . We thus used mortality rate as the primary outcome in this meta-analysis, because it allows us to control the risk of detection bias associated with the diagnosis of HAP, notably in open-label trials.
Previous reviews and meta-analyses have already reported a reduction in the risk of death with SDD [53] . In clinical practice, however, SDD is rarely used in ICUs [54] and was not even considered in a recent European survey that evaluated the approaches for HAP prevention in ICUs [55] . The most likely explanation Figure 3 . Intensive care unit (ICU) mortality rates in trials evaluating selective digestive decontamination. A, Forest plot for mortality in randomized clinical trials evaluating the effects of digestive decontamination in critically ill patients . B, Funnel plot for mortality rates in randomized controlled trials depicts the effects of digestive decontamination on mortality. The x-axis represents the effect; the y-axis, precision. C, Meta-regression analysis exploring the interaction between survival benefit with digestive decontamination and the incidence of mortality in the control group (y = −0.83x + 1.107; P = .07). Abbreviations: CI, confidence interval; M-H, Mantel-Haenszel; RR, risk ratio; SE (Log RR), standard error of the logarithm of the risk ratio. Figure 4 . Hospital-acquired pneumonia in critically ill patients receiving a strategy for preventing hospital acquired pneumonia. All pooled estimates used the random effects model. Boldface P values indicate significant differences (P < .05). Abbreviations: CI, confidence interval; ET, endotracheal tube; NA, not applicable; PEEP, positive end-expiratory pressure; RCT, randomized controlled trials; SDD, selective digestive decontamination; SOD, selective oropharyngeal decontamination.
for the infrequent use of SDD is concern about the risk for emerging antimicrobial resistance during treatment [44, 56, 57] . However, in the largest trial of SDD [14] , the percentages of resistant bacteria causing ICU-acquired bacteremia were not significantly altered in patients treated with SDD, compared with controls. Moreover, in a recent meta-analysis including microbiological data issue from 35 studies, no relationship was found between the use of SDD and development of antimicrobialresistance in pathogens [58] . In the subgroup of patients with infection due to gram-negative bacteria, SDD was associated with a decreased risk of resistance to cephalosporins and quinolones [58] . This surprising result may be explained by the reduction in the total daily doses of antibiotics that has been reported with SDD [14] . The lack of a proof for increased antimicrobial resistance in numerous studies suggests that the perceived risk of selection of resistant bacteria does not justify the low rate of SDD use in clinical practice. However, the long-term risk of emergence of resistance needs to be better investigated before we can rule out this potential side effect of SDD.
Given concerns regarding acquisition of bacterial resistance, it has been suggested that SDD may be used in selected populations, but little information is available regarding the populations that could be eligible for SDD. In particular, medical versus surgical reasons for ICU admission are not reliable criteria in selecting patients for SDD [59] . The result of the metaregression ( Figure 2C ) suggests that SDD is more effective in patients with a high risk of death. In 2 systematic reviews, SDD seemed particularly effective in patients with multiple organ dysfunction syndrome or with a high risk for bacteremia [60] . Taken together, these data suggest that the use of SDD could be limited to patients with a high risk of death, such as those presenting with acute organ failure on admission.
Several regimens of SDD have been proposed, and the use of a systemic antimicrobial therapy is one of the main differences Figure 5 . Duration of mechanical ventilation in critically ill patients receiving a strategy for preventing hospital-acquired pneumonia. All pooled estimates used the random effects model. Boldface P values indicate significant differences (P < .05). Abbreviations: CI, confidence interval; ET, endotracheal tube; NA, not applicable; PEEP, positive end-expiratory pressure; RCT, randomized controlled trial; SDD, selective digestive decontamination; SOD, selective oropharyngeal decontamination; WMD, weighted mean difference.
between them. We found that systemic antimicrobial therapy is essential to a decrease in the risk of mortality. The recent demonstration that the distal respiratory flora is not distinct from the upper airway microbiome in healthy lungs [61, 62] suggests that HAP results from an increased population of distal lung bacteria rather than colonization from the digestive tract. This hypothesis can explain why the application of an oral paste of nonabsorbable antibiotics, which has no effect on the lung microbiome, is not sufficient to prevent HAP and reduce the risk of death. Finally, the current results argue that protocols of SDD should always include a short course of systemic antimicrobial therapy and question the importance of the oral paste.
This meta-analysis has some limitations. First, our study combined different types of interventions. This strategy of analysis has already been used to estimate the attributable mortality of HAP [46, 63] , and it will enable intensivists to prioritize strategies for implementation in clinical practice. Second, the number of patients in the SDD analyses is greater than the number for any other intervention, which results in a higher power for SDD than for other strategies. Thus, the current meta-analyses cannot rule out the efficiency of strategies with fewer included patients. Third, the prevention of ventilator-associated pneumonia was analyzed together with that of HAP. However, pathogens involved in HAP are similar regardless of whether or not HAP is acquired during mechanical ventilation, thereby Figure 6 . Duration of ICU stay for critically ill patients receiving a strategy for preventing hospital-acquired pneumonia. All pooled estimates used the random effects model. Boldface P values indicate significant differences (P < .05). Abbreviations: CI, confidence interval; ET, endotracheal tube; ICU, intensive care unit; NA, not applicable; PEEP, positive end-expiratory pressure; RCT, randomized controlled trial; SDD, selective digestive decontamination; SOD, selective oropharyngeal decontamination; WMD, weighted mean difference.
suggesting that preventive strategies should be efficient with both HAP and ventilator-acquired pneumonia [64] . Finally, the existing literature on SDD has mainly considered shortterm impacts on morbidity and mortality rates. If SDD eventually leads to increased prevalence of resistant bacteria, then the short-term benefits could be reversed by increases in failure of curative antimicrobial therapy.
In conclusion, the current meta-analysis, which includes 157 randomized studies, highlights the benefits preventing HAP in decreasing death rates in critically ill patients. When specific interventions are considered separately, SDD with systemic antimicrobial therapy should be considered first in critically ill patients, mainly in those with acute organ failure and at high risk for death. Ongoing trials should (1) enhance the selection of patients who may benefit from SDD and determine the minimal efficient duration of systemic antimicrobial therapy; (2) compare systemic antimicrobial therapy, with or without digestive decontamination; (3) determine the optimal antimicrobial therapy in patients treated with SDD who develop a subsequent infection; and (4) assess the long-term risk for emergence of multiple-drug-resistant bacteria.
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